BIO Stock Overview
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €41.20 |
| 52 Week High | €44.80 |
| 52 Week Low | €40.60 |
| Beta | 0.26 |
| 1 Month Change | -2.37% |
| 3 Month Change | -2.37% |
| 1 Year Change | -2.37% |
| 3 Year Change | 48.74% |
| 5 Year Change | 69.55% |
| Change since IPO | 327.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIO | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.4% | -4.9% | -1.5% |
| 1Y | -2.4% | -19.9% | 0.9% |
Return vs Industry: BIO exceeded the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: BIO underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| BIO volatility | |
|---|---|
| BIO Average Weekly Movement | 2.2% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BIO has not had significant price volatility in the past 3 months.
Volatility Over Time: BIO's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,426 | Peter Janssen | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine.
Biotest Aktiengesellschaft Fundamentals Summary
| BIO fundamental statistics | |
|---|---|
| Market cap | €1.39b |
| Earnings (TTM) | €127.00m |
| Revenue (TTM) | €684.60m |
8.9x
P/E Ratio1.7x
P/S RatioIs BIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO income statement (TTM) | |
|---|---|
| Revenue | €684.60m |
| Cost of Revenue | €404.30m |
| Gross Profit | €280.30m |
| Other Expenses | €153.30m |
| Earnings | €127.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 3.21 |
| Gross Margin | 40.94% |
| Net Profit Margin | 18.55% |
| Debt/Equity Ratio | 126.7% |
How did BIO perform over the long term?
See historical performance and comparison